Acumen Pharmaceuticals: Altitude-AD Failure Destroys The Investment Thesis (Rating Downgrade)
Acumen Pharmaceuticals' lead Alzheimer's drug sabirnetug failed to show clinical efficacy in the ALTITUDE-AD trial. See why ABOS stock is downgraded to a sell.